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Abstract
We have recently demonstrated that single shot vaccinations against tetanus and diphtheria do not lead to
long-lasting immunity against diphtheria in elderly persons despite administration at 5 year intervals. In the present
study we have immunized a group of young adults against tetanus and diphtheria to compare the pre- and 28 days
post-vaccination immune responses in the young group with results of the same vaccination performed in an elderly
group of a previous study. We also studied protection in both groups 5 years after vaccination. We compared antibody
titers at all three time points and also analyzed the T cell responses in both age groups 5 years after vaccination.
Before vaccination 9 % of the elderly persons were not protected against tetanus, and 48 % did not have protection
against diphtheria. In the young group all participants were protected against tetanus, but 52 % were also unprotected
against diphtheria before vaccination. 28 days after vaccination 100 % of all participants had protective antibody
concentrations against tetanus and only a small percentage in each age group (<10 %) was unprotected against
diphtheria. 5 years later, 100 % of both cohorts were still protected against tetanus, but 24 % of the young and
54 % of the elderly group were unprotected against diphtheria. Antibody concentrations against diphtheria
measured by ELISA correlated well with their neutralizing capacity. T cell responses to tetanus and diphtheria did
not differ between young and old persons. We conclude that booster vaccinations against tetanus and diphtheria
according to present recommendations provide long-lasting protection only against tetanus, but not against
diphtheria, independently of age. In elderly persons, the level of protection is even lower, probably due to intrinsic
age-related changes within the immune system and/or insufficient vaccination earlier in life.
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Introduction
Immunization is one of the most successful and cost-
effective health interventions against infectious diseases.
Since its introduction the mortality and incidence rate of
many diseases has been reduced dramatically, as for instance
for measles, rubella or diphtheria [1, 2]. Tetanus and
diphtheria vaccines, which contain the bacterial toxoids
in combination with aluminum salts, are among the
most frequently used vaccines worldwide. The current
WHO’s vaccination recommendation against tetanus
and diphtheria comprises a primary vaccination series
during childhood and regular booster vaccinations
throughout life [3, 4]. In Austria, vaccination against
tetanus and diphtheria is recommended every 10 years
for adults and every 5 years for people above 60 years
of age [5]. However, we and others have repeatedly re-
ported insufficient antibody (Ab) concentrations against
both antigens (specific Abs <0.1 IU/ml) in adults, particu-
larly in the elderly [6–12]. The proportion of unprotected
individuals varied between 2 and 60 % for tetanus and be-
tween 29 and 70 % for diphtheria. Lack of protection in
elderly persons is suggested to be due to intrinsic changes
within the immune system [13], but may also be due to
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lack of, or incomplete primary immunization or the
absence of regular booster shots.
We immunized an elderly cohort in 2005 providing
the participants with one shot of Repevax® and measured
pre- and post-vaccination Ab concentrations [11]. Al-
though protection against tetanus was sufficient in the
majority of participants before and after vaccination,
protection levels against diphtheria were very low before
but almost 100 % 28 days after vaccination. According
to Austrian recommendations, the participants were in-
vited for a booster shot (Boostrix®) 5 years later, in 2010.
Surprisingly, protection against diphtheria was once again
low, almost as low as at the time of the first recruitment
in 2005, demonstrating that our initial vaccination strategy
had failed to induce long-lasting immunity against diph-
theria in this age group [12]. In order to find out whether
the short-lasting immunity observed in old people was
only due to their advanced age, we recruited a young
cohort and administered one dose of BoostrixPolio® to
compare pre- and post-immunization Abs with the elderly
cohort. After another 5 years, in 2015, Abs and T cell re-
sponses against tetanus and diphtheria were analyzed in
both age groups. We demonstrated that protection against
tetanus was 100 % in both age groups, but that protection
against diphtheria was lost in 54 % of the elderly group.
Interestingly, 24 % of the young cohort did also not have
protective Ab concentrations against diphtheria, in spite
of an only 5 year interval since the last vaccination.
Material and methods
Study cohorts and protocol
87 healthy, elderly adult volunteers (median age 71 years,
range 66–92 years; 47 females), who had received one
dose of Repevax® (Sanofi Pasteur MSD) in 2005 [11], were
vaccinated once more against tetanus, diphtheria and per-
tussis (Boostrix®, GlaxoSmithKline) 5 years later in 2010
[12]. Pre- and 28 days post-vaccination Ab concentrations
of the 2010 vaccination were now compared with corre-
sponding data from a group of 46 healthy, young adult
volunteers (median age 29 years, range 24–40 years; 29
females) which was recruited in 2010 and received one
booster vaccination against tetanus, diphtheria, pertussis
and polio (Boostrix®-Polio, GlaxoSmithKline). Their
previous booster shot was well documented and dated
back more than 10 years. All vaccinations were performed
in accordance with the official recommendations by the
Austrian health authorities [5]. Young and old participants
were recruited from the general population and all par-
ticipants of the old cohort were community-dwelling.
Persons with chronic viral infection (Human Immuno-
deficiency virus, Hepatitis B virus, Hepatitis C virus),
transplant recipients and patients under immunosuppres-
sive or chemotherapy were not included in the study.
Routine laboratory parameters (liver and kidney function,
blood count) were determined at the time point 2010 and
all participants were shown to be in good health [12]. All
participants were invited back 5 years later, in 2015, for
the analysis of the level of protection against tetanus and
diphtheria by measuring Abs as well as T cell function.
Due to various reasons (such as unwillingness to partici-
pate, change of address, ill health, death or meeting one of
the exclusion criteria), only 27 elderly and 17 young adults
could be studied in 2015. Exclusion criteria were the same
for both groups in 2010 and 2015, namely chronic viral in-
fections (HIV, HBV, HCV), transplant reception, cancer as
well as immunosuppressive therapy. Pregnant or lactating
females were also excluded from the study. We checked
whether the participants re-recruited in 2015 were repre-
sentative for the original larger cohorts, and found that
neither age nor sex were different. We also compared pre-
and post-vaccination Ab concentrations measured in 2010
between the total cohort and the sub-cohorts available for
further analysis in 2015 and did not find any statistically
significant difference.
Preparation of plasma and peripheral blood mononuclear
cells (PBMCs)
Heparinized blood was drawn from the arm vein and
fractionized by density gradient centrifugation using
Ficoll-Paque™ Plus (GE Healthcare) to collect plasma
and PBMCs. PBMCs were used freshly and plasma was
stored at −20 °C.
Determination of Ab concentrations by ELISA
Microtiter plates were coated with 1 μg/ml tetanus or
diphtheria toxoid (Statens Serum Institute) and blocked
with 0.01 M Glycin. Plasma samples were tested in du-
plicates. Peroxidase-labeled rabbit anti-human IgG Ab
(Chemicon/Millipore) was used as secondary Ab. IgG Abs
were quantified in IU/ml using standard human anti-tetanus
and anti-diphtheria sera (National Institute for Biological
Standards and Control). The detection limit of the assays
used was 0.01 IU/ml, and values below this concentration
were set to 0.005 IU/ml for calculation of geometric mean
concentrations (GMC). Ab concentrations above 0.1 IU/ml
were considered as protective [3, 4].
Determination of Abs against diphtheria by neutralization
assay
Plasma samples were incubated for one hour with 0.1 M
2-mercaptoethanol in order to eliminate IgM Abs. After
heat inactivation at 56 °C for 30 min serial dilutions ran-
ging from 1:20 to 1:4800 were prepared using Dulbecco’s
modified eagle’s medium (Sigma Aldrich) containing 2 %
fetal calf serum (FCS; Sigma Aldrich) and 1 % Penicillin-
Streptomycin (Sigma Aldrich). The pre-diluted samples
were incubated with diphtheria toxin (8 ng/ml; Sigma
Aldrich) for 90 min. This mixture was transferred into
Grasse et al. Immunity & Ageing  (2016) 13:26 Page 2 of 9
96-well tissue culture plates seeded with 15.000 Vero
cells 24 h earlier. After 48 h Vero cells were stained with
crystal violet. Living cells were stained violet, indicating
that the Abs were able to neutralize the diphtheria toxin.
All incubations were performed at 37 °C and 5 % CO2.
Flow cytometric analysis of cytokine production
Cytokine production of antigen-specific CD4+ T cells was
induced by stimulation of PBMCs with 10 μg/ml tetanus-
or diphtheria-toxoid at 37 °C for 6 h with 10 μg/ml Brefeldin
A added after the first hour of stimulation. PBMCs were
washed with PBS and stained with Zombie Violet™ Fixable
Viability dye (Biolegend) for 20 min at RT and washed with
FACS buffer (PBS + 2 mM EDTA+ 2 % FCS+NaN3). Cells
were stained with anti-CD3-BV510 (clone: UCHT1; BD
Biosciences), anti-CD4-PE-Cy™7 (clone: SK3; BD Biosci-
ences) and anti-CD45RO-PerCP-Cy™5.5 (clone: UCHL1;
BD Biosciences) for 20 min at 4 °C. After washing with
FACS buffer, cells were fixed and permeabilized using the
BD Cytofix/Cytoperm™ kit (BD Biosciences) following
manufacturer’s instructions. Cells were then stained with
anti-IFN-γ-FITC (clone: B27; BD Biosciences), anti-TNF-
α-PE (Mab11; BD Biosciences), anti-IL2-APC (clone:
MQ1-17H12; BD Biosciences), anti-IL4-PE (clone: 8D4-8;
BD Biosciences), anti-IL10-APC (clone: JES3-19 F1; Biole-
gend), anti-IL17-PE (clone: eBio64DEC17; eBioscience),
anti-IL21-Alexa Fluor®647 (clone: 3A3-N2.1; BD Biosciences),
anti-TGF-β1-PE (clone: TW4-9E7; BD Biosciences) and
anti-GM-CSF- Alexa Fluor®647 (clone: BVD2-21C11;
BD Biosciences) for 30 min in BD Cytoperm™ (BD Biosci-
ences) at 4 °C. After washing with PBS, cells were mea-
sured using the FACS canto II cytometer (BD) and
analyzed using FlowJo software (V 10.0.7.). CD4+ memory
cells were gated as CD3+CD4+CD45RO+. The unstimu-
lated controls were subtracted from the antigen-specific
samples for each cytokine and donor.
Statistical analysis
Group wise comparisons for tetanus- and diphtheria-
specific Abs as well as for antigen-specific cytokine-pro-
ducing T cells were performed using the Wilcoxon test.
The Wilcoxon-signed rank test was applied for paired data
and the Wilcoxon rank-sum test for unpaired data.
The frequency of persons protected/unprotected against
tetanus and diphtheria in the young and the elderly group
was compared using the chi-square test.
Spearman rank correlations were applied to study re-
lations between neutralizing capacity and total concen-
trations of diphtheria-specific Abs, Ab concentrations and
the time since the last vaccination, as well as to study
the relationship between Abs and cytokine production
in T cells.
The level of significance for all tests was α = 0.05. Ac-
cordingly, the critical value for the chi-square test was
x2 = 3.84.
SPSS version 23 (SPSS Inc., Chicago, USA) was used
for all statistical analyzes.
Results
Antibody concentrations against tetanus and diphtheria
in young and elderly persons measured by ELISA
The geometric mean concentrations (GMCs) of tetanus-
and diphtheria-specific Abs at three different time points
are shown in Fig. 1: Pre-vaccination Ab concentrations
in 2010, post-vaccination Ab concentrations on day 28
in 2010 and 5 years later in 2015. For tetanus (Fig. 1a)
Ab concentrations were generally high, well above the
protective level, and were not different in the two age
groups. For diphtheria (Fig. 1b), GMCs were around the
protective level in both age groups before vaccination in
2010, but well in the protective range 28 days after vac-
cination. Five years later, expectedly Ab concentrations
had decreased in both age groups, but were significantly
higher in the young than in the elderly cohort. In 2015
Ab concentrations in the young group were also higher
than the pre-vaccination values in 2010. In contrast, Ab
concentrations in the old cohort were back to the pre-
vaccination level in 2010 (Fig. 1b).
Percentage of young and elderly persons protected against
tetanus and diphtheria
Corresponding to the high Ab concentrations against
tetanus, 100 % of both age groups were protected against
this antigen. A small proportion of elderly persons who
had been unprotected before vaccination in 2010 were
protected after the vaccination and were still protected
5 years later (Fig. 2a).
The situation was different for diphtheria (Fig. 2b). In
both age groups, about half of the cohort did not have
protective Ab concentrations before vaccination in 2010.
Most participants from both age groups had protective
Ab concentrations 4 weeks after vaccination, but a small
number of persons (<10 %) from each age group remained
unprotected. After 5 years, the percentage of unprotected
persons had dropped in both age groups, with 54 % of the
elderly group and 24 % of the young group being unpro-
tected, which was a significant difference (Fig. 2b).
Functional analysis of diphtheria-specific Abs
In view of the fact that Ab concentrations against diph-
theria were quite low in some persons, we analyzed the
functionality of diphtheria-specific Abs in young and older
adults. We therefore measured the neutralizing capacity of
diphtheria-specific Abs from 27 elderly and 17 young
adults at three time points: immediately before and
28 days after vaccination (2010) and 5 years later
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Fig 1 Tetanus- and diphtheria-specific Ab concentrations measured by ELISA. Tetanus- a and diphtheria- b specific Ab concentrations of young and
elderly adults are shown as geometric mean concentrations (GMCs) ± 95 % confidence interval. Ab concentrations of young and old donors were
compared before (day 0_2010), 4 weeks after (day 28_2010) as well as 5 years after (2015) a tetanus and diphtheria booster shot. Wilcoxon-signed rank
test was applied for comparisons within the age groups (paired data) and the Wilcoxon rank-sum test was applied for comparisons among the age
groups (unpaired data). * p = 0.0266 (young vs. old in 2015) ** p = 0.0052 (young pre-vaccination 2010 vs. 2015)
Fig 2 Level of protection against tetanus and diphtheria. Tetanus- a and diphtheria- b specific Ab concentrations from young and elderly adults
were measured by ELISA. A concentration above 0.1 IU/ml was considered as protective. Frequencies of protected (grey) and unprotected (black)
individuals are shown. Plasma samples were collected before (day 0_2010), 4 weeks after (day 28_2010) as well as 5 years after (2015) the booster
shot. Chi-squared test was applied for statistical analysis. * x2 = 4.36 (x2crit = 3.84)
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(2015). The neutralizing capacity and diphtheria-specific
Ab concentrations measured by ELISA were highly corre-
lated (p <0.0001, rs >0.821 in both age groups at all time
points, Fig. 3).
The impact of time since the last vaccination on Ab
concentrations
Recent vaccination history was synchronized for the
older cohort, as they had received tetanus and diphtheria
vaccinations in the context of our studies in 2005 and
2010 [11, 12]. In contrast, the time since the last vaccin-
ation before the recruitment in 2010 varied considerably
within the young group. Correlations between pre- and
post-vaccination Ab concentrations in 2010 and the time
since the last vaccination were therefore only analyzed
in the young group (Fig. 4). For tetanus there was no
correlation between Ab concentrations and the time
point of the last vaccination (Fig. 4a). In contrast, for
diphtheria, there was a significant correlation between
Ab concentrations and the time since the last vaccination
(Fig. 4b). This correlation was most pronounced for the
Ab concentrations 28 days after vaccination, indicating
that regular booster vaccinations against diphtheria are
important not only for the maintenance of Ab levels, but
also for the success of booster vaccinations.
T cell responses to tetanus and diphtheria
In a previously published study on elderly adults [12] we
found a weak correlation between IL-5-producing T cells
measured by Elispot and diphtheria-specific Abs. In the
present study, a detailed analysis of cytokine production
by CD4+ memory cells was performed at the 2015 time
point using flow cytometry. The production of 9 cytokines
(IFN-γ, TNF-α, IL-2, IL-4, IL-10, IL-17, IL-21, TGF-β,
GM-CSF) following in vitro stimulation of PBMCs with
tetanus (Fig. 5a and c) and diphtheria (Fig. 5b and d)
toxoid was analyzed, and was found to be similar in
young (Fig. 5a and b) and elderly (Fig. 5c and d) adults.
The production of more than one cytokine was detected
in CD4+ memory cells of all donors. Tetanus-specific T
cells of young and old donors produced 5.8 ± 1.2 (mean ±
SD) and 5.4 ± 1.8 cytokines, respectively (n.s.; Wilcoxon
rank-sum test). 4.2 ± 1.0 and 4.0 ± 1.4 cytokines were
detected after stimulation with diphtheria toxoid in T
cells of young and old donors, respectively (n.s.; Wilcoxon
rank-sum test). The frequency of all antigen-specific
cytokine-producing T cells was similar in both age groups
for tetanus and diphtheria (n.s.; Wilcoxon rank-sum test).
Correlations between Ab concentrations and cytokine pro-
duction were also performed (Table 1). There was no cor-
relation between tetanus Ab concentrations and cytokine
production by tetanus-specific CD4+ memory T cells,
whereas a weak correlation was found between diphtheria-
specific Abs and diphtheria-specific IL-2-, IL-21- and GM-
CSF-producing CD4+ memory T cells. All these correla-
tions were performed with pooled data from both age
groups (n = 44) due to the low sample sizes in each group.
Results were similar when both age groups were analyzed
separately, but did not reach statistical significance.
Discussion
In a previous study, we investigated the level of protec-
tion against tetanus and diphtheria in an elderly popula-
tion and analyzed the immune response to tetanus and
diphtheria following two doses of vaccine applied at a
5 year interval [12]. The level of protection against tetanus
was much higher than the one against diphtheria at both
time points and reached almost 100 % protection 4 weeks
after the booster shots. With the applied vaccination
strategy we followed official Austrian recommendations
according to which persons of more than 60 years of
age should receive a booster vaccination every 5 years.
It was surprising that even after this relatively short
period of time almost half of the cohort had lost pro-
tective Ab concentrations against diphtheria and were
again unprotected 5 years after the first vaccination.
Fig 3 Diphtheria-specific Abs measured by ELISA and neutralizing assay. The concentrations of diphtheria-specific Abs measured by ELISA are shown
in correlation to the highest plasma dilution factor able to neutralize diphtheria toxin (8 ng/ml). Diphtheria-specific Abs were compared in samples
taken before (day 0_2010), 4 weeks after (day 28_2010) as well as 5 years after (2015) the booster shot. Elderly adults (n = 27) are represented by empty
diamonds and solid trend-lines, young adults (n = 17) by filled dots and dashed trend-lines. Spearman rank correlation was applied and
correlation coefficients and p-values were determined
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Protection could be re-obtained in 94 % of the cohort
28 days after a second shot of diphtheria vaccine. It was
the goal of the present study to re-analyze the cohort
after another 5 years and additionally to compare them
with a young cohort in order to clarify the role of age-
related intrinsic changes within the immune system.
We now demonstrate that in spite of having applied
the tetanus/diphtheria vaccine twice, diphtheria-specific
Ab concentrations had again dropped to unprotective
levels in more than half of the elderly cohort. This was not
the case for tetanus, against which 100 % of the elderly co-
hort were now protected. Surprisingly, the situation was
similar, although to a lesser extent, in the young group, in
which 24 % were unprotected despite the fact that the
last booster shot had been applied only 5 years earlier.
Diphtheria vaccination is recommended every 10 years
for young adults. It can be speculated that Ab concentra-
tions will drop below protective levels in an even larger
proportion of the young cohort until they receive the next
booster vaccination. Similar to the elderly cohort, 100 %
of the young persons had protective Ab concentrations
against tetanus.
These results suggest that, although age-related changes
in the immune system may play some role, diphtheria vac-
cination does not provide satisfactory results at any age.
This may be due to several reasons: As depicted in Fig. 1,
in both age groups the levels of diphtheria-specific Abs
were one order of magnitude lower than of tetanus-
specific Abs. The same finding has been reported by other
groups [14–16]. Low Ab concentrations against diphtheria
following booster vaccination compared to tetanus are
presumably due to the fact that vaccines used for booster
vaccination in adults contain much less diphtheria toxoid
than the vaccines used for primary immunization. The re-
duction of the amount of diphtheria toxoid per dose was
originally implemented because of reported side effects
after vaccination with higher diphtheria concentrations
[17–19]. However, these reports date back quite a while
and it is presently not clear whether improved production
and purification processes would make a higher diphtheria
Fig 4 Impact of vaccination history on Ab concentrations in young persons. Tetanus- a and diphtheria- b specific Ab concentrations are shown
in correlation to the time since the last vaccination before recruitment for this study. Correlations were calculated using Ab concentrations assessed in
young adults (n = 46) before (day 0_2010) and 4 weeks after (day 28_2010) the tetanus/diphtheria vaccination in 2010. Spearman rank correlation
coefficients (rs) and p-values are indicated
Grasse et al. Immunity & Ageing  (2016) 13:26 Page 6 of 9
toxoid dose possible without adverse events. It might thus
be a possibility to evaluate higher diphtheria toxoid doses
in adults in order to achieve longer-lasting immunity. As
the neutralizing activity of diphtheria Abs is not impaired,
neither in young nor in elderly persons, it would be
sufficient to increase the titers to achieve longer-
lasting immunity. Similar Ab quality in young and old
persons has also been described for TBE and influenza
vaccination [20, 21].
In this context it was also of interest that in the young
group the response to the diphtheria booster shot was
improved when the last booster immunization did not
date back too long. This finding demonstrates the im-
portance of regular booster immunizations throughout
adulthood. However, awareness of this necessity seems
to be insufficient among medical staff and young adults,
considering the fact that the last vaccination against
Fig 5 Cytokine production by tetanus- and diphtheria-specific CD4+ memory T cells. PBMCs were stimulated for 6 h with 10 μg/ml tetanus (a c)
or 10 μg/ml diphtheria toxoid (b d) in the presence of Brefeldin A (5 h). Frequencies of CD4+ memory T cells producing IFN-γ, TNF-α, IL-2, IL-4,
IL-10, IL-17, IL-21, TGF-β and GM-CSF were measured by flow cytometry. Data from young (a b; n = 17) and elderly (c d; n = 27) adults are shown.
A representative example for the gating strategy is shown in Additional file 2: Figure S1
Table 1 Correlations between antigen-specific cytokine-
producing CD4+ memory T cells and Abs
Tetanus Diphtheria
Cytokine rs p-value rs p-value
IFN-γ −0.059 0.715 0.195 0.204
TNF-α −0.078 0.626 0.214 0.180
IL-2 0.067 0.678 0.398 0.010
IL-4 −0.090 0.563 0.067 0.665
IL-10 0.001 0.996 0.091 0.570
IL-17 −0.223 0.160 −0.110 0.494
IL-21 −0.018 0.913 −0.309 0.049
TGF-β 0.054 0.739 0.200 0.192
GM-CSF −0.019 0.906 0.347 0.026
Correlations were performed with pooled data from both age groups (n = 44)
Abbreviation: rS spearman’s rank correlation coefficient
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diphtheria dated back up to 36 years in our young cohort.
This means that some participants had never received an
adult booster shot.
Documentation of the primary vaccination is frequently
poor for adults and particularly for the elderly as shown
in several studies [7, 9]. It is therefore not clear,
whether all participants had received a complete pri-
mary immunization. At first enrollment the date of the
last vaccination against diphtheria was documented for
only 47 % of the participants [12]. Whether single booster
shots with reduced diphtheria content even at relatively
short intervals might eventually lead to long-lasting pro-
tection under these circumstances seems doubtful in view
of our results, which demonstrate that even two shots at a
5 year interval cannot retain protective immunity for the
duration of this time period in elderly persons.
How can this dilemma be solved? Improved vaccines
specifically tailored for the needs of the 50+ generation
could be designed, but which requirements should such
vaccines fulfill? A stronger effect on T cells might be one
strategy to improve Ab responses. Diphtheria-specific T
cell responses were not compromised in our elderly cohort,
and results showed weak but significant correlations
between T cell cytokines and Ab concentrations for
diphtheria; however, no correlations were seen for tetanus,
indicating that T cell help might only be needed in the
case of poor Ab responses. Although aluminum salts have
been used for almost one century as adjuvants in order to
improve the immunogenicity of protein vaccines [22], the
detailed mode of action is unclear and still a topic of re-
search [23, 24]. Thus, aluminum adjuvants may not be the
ideal candidates to achieve a better T cell help. It was of
interest that GM-CSF was among the cytokines, which
showed a positive correlation with diphtheria Ab concen-
trations. GM-CSF is recognized as an adjuvant candidate
and has been tested in combination with several types of
immunization. In humanized mice, GM-CSF treatment
has been shown to significantly improve antigen-specific
Ab responses following immunization with H5N1 influ-
enza vaccine [25]. GM-CSF has also been successfully
used to overcome immune tolerance in a mouse model
for therapeutic vaccination against hepatitis B [26]. Ad-
ministration of GM-CSF improved immune responses to
crude leishmania antigen vaccine in healthy adults [27].
GM-CSF is used for dendritic cell (DC) maturation in
vitro and may also be used to improve this process in the
elderly, as age-related defects in DC function and mat-
uration have been described (reviewed in [28, 29]). This
might trigger the T cell/B cell axis in order to achieve bet-
ter Ab production. Alternatively, GM-CSF-producing
memory T cells could also be specifically stimulated by
other new adjuvants.
In summary, we would like to point out that tetanus
vaccination following present recommendations seems
to yield satisfactory results, which is not the case for
diphtheria. As a minimum measure, regular booster
shots should be applied in young adults, a strategy which
is, however, unlikely to be successful in elderly persons.
Therefore efforts to generate new vaccines and/or vac-
cination strategies are needed to elicit better protection
in the elderly. This may also be necessary for the pertus-
sis component of the vaccine which has been studied in
the past [11], but has not been included in the present
study.
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